← Search & browse all drugs

ruxolitinib

L01EJ01

Forms & Strengths

Oral tablets: 5 mg, 10 mg, 15 mg, 20 mg
Topical cream: 1.5%

Adult Dosing

Myelofibrosis: 15-20 mg PO BID based on baseline platelet count
Polycythemia vera: 10 mg PO BID
Acute graft-versus-host disease: 5 mg PO BID
Chronic graft-versus-host disease: 10 mg PO BID
Atopic dermatitis (topical): Apply thin layer BID up to 20% BSA

Pediatric Dosing

Acute graft-versus-host disease (>=12 years): 5 mg PO BID
Chronic graft-versus-host disease (>=12 years): 10 mg PO BID
Atopic dermatitis (>=12 years, topical): Apply thin layer BID up to 20% BSA

Indications

Intermediate or high-risk myelofibrosis
Polycythemia vera resistant to or intolerant of hydroxyurea
Acute graft-versus-host disease steroid-refractory
Chronic graft-versus-host disease after failure of 1 or 2 lines of therapy
Atopic dermatitis short-term and intermittent long-term therapy (topical)

Mechanism of Action

Selective Janus kinase (JAK) inhibitor with high selectivity for JAK1 and JAK2
Inhibits JAK-STAT signaling pathway, reducing proliferation and inducing apoptosis in malignant cells
Downregulates inflammatory cytokine production involved in myeloproliferative neoplasms and GVHD

Contraindications

Severe hepatic impairment
Active serious infection
Known hypersensitivity to ruxolitinib

Adverse Reactions

Thrombocytopenia
Anemia
Neutropenia
Weight gain
Dizziness
Headache
Herpes zoster reactivation
Urinary tract infections
Increased risk of malignancies (non-melanoma skin cancer)

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole): Reduce ruxolitinib dose
Dual CYP3A4 and CYP2C9 inhibitors: Reduce ruxolitinib dose
Strong CYP3A4 inducers (e.g., rifampin): May decrease ruxolitinib efficacy
Immunosuppressants: Increased risk of severe infections

Curated Content: Needs Vetting Before Put to Clinical Use